Niagen Bioscience (NAGE) in Focus: Can Its NAD+ IP and Pending Catalysts Justify a Higher Valuation?
After recent share price declines, Niagen Bioscience is drawing renewed investor scrutiny. The biotech firm's valuation story hinges on its proprietary NAD+ technology, upcoming B2B product launches, and critical clinical data readouts expected later this year.